latest update:
[TrialBase DB]

trial summary · NCT06449313

Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features

A Phase 2 Single-arm Study of Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement or Other High Risk Features

Trial record from the TrialBase DB dataset, status RECRUITING, condition Non-small Cell Lung Cancer Stage III, sponsored by Georgetown University. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT06449313phase PHASE2enrollment 21start 2026-11

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

The goal of this clinical trial is to learn about neoadjuvant cemiplimab with histology-specific chemotherapy followed by resection and adjuvant cemiplimab in stage 3 non-small cell lung cancer (NSCLC) with select N3 lymph node involvement or other high-risk subsets in which there is no consensus on resectability. The main question it aims to answer is whether patients with stage 3 NSCLC with involvement of lymph nodes can undergo surgery to remove the cancer after receiving treatment with chemotherapy + immunotherapy. Participants will receive FDA-approved chemotherapy called platinum-doublet chemotherapy together with an immunotherapy drug targeting the immune marker PD-1 called cemiplimab. Patients will receive a 3 drug combination for 4 total treatments given every 3 weeks before surgery. After surgery, patients will have the option to undergo radiation therapy if it is recommended by their treatment team. After this, they will receive cemiplimab every 3 weeks for one year.

Source record: https://clinicaltrials.gov/study/NCT06449313

Facts

registry idNCT06449313
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionNon-small Cell Lung Cancer Stage III
sponsorGeorgetown University
sponsor classOTHER
enrollment21
start date2026-11
primary completion2027-12
completion2032-09
results postednot reported

Conditions

  • Non-small Cell Lung Cancer Stage III

Interventions

  • Cemiplimab-Rwlc

Countries

  • United States

Intervention types: DRUG

Work with this record